

Not for distribution, directly or indirectly, in the United States of America, Australia, Canada or Japan

Share Capital Increase: Offer to Market of the unexercised rights closed early

Milan, 2 April 2015 – MolMed S.p.A. (“**MolMed**” or the “**Issuer**”), following the press release issued on 30 March 2015 and the related Notice (in Italian) published on the newspaper *Milano Finanza* on 31 March 2015, announces that during the second trading session held today, all of the No. 1,773,220 rights not exercised during the offering period (the “**Unexercised Rights**”) for the subscription of No. 1,418,576 newly issued MolMed ordinary shares (the “**Shares**”) have been sold, for a total amount of Euro 178,208.61.

The exercise of the Unexercised Rights purchased during the offer to the Market and, therefore, the subscription of the related Shares shall be carried out, under penalty of forfeiture, by and no later than the third trading day following the early closing notification, and therefore by 9 April 2015.

The Unexercised Rights will be made available to purchasers through authorized intermediaries members of the centralized management system of Monte Titoli S.p.A. and may be used to subscribe the Shares - having the same characteristics of the outstanding MolMed ordinary shares as of the relevant issuance date and with regular entitlement – at a price of Euro 0.2660 per share (of which Euro 0.0471 attributed to share capital and the remaining amount to share premium) based on a ratio of no. 4 Shares for every No. 5 Unexercised Rights.

The Registration Document, the Information Note and the Summary Note, as well as the Supplement, are available to the public at the registered office of MolMed, in Milan (Italy), via Olgettina, n. 58 and on MolMed’s website (www.molmed.com).

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

This communication does not constitute an offer or an invitation to subscribe for or purchase any Securities. The securities referred to herein have not been registered and will not be registered in the United States under the U.S. Securities Act of 1933, as amended (the “Securities Act”) , or in Australia, Canada or Japan or any other jurisdiction where such an offer or solicitation would require the approval of local authorities or otherwise be unlawful. The securities may not be offered or sold in the United States or to U.S. persons unless such securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. Copies of this announcement are not being made and may not be distributed or sent into the United States, Canada, Australia or Japan.

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes two antitumour therapeutics in clinical development:

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325
info@molmed.com - www.molmed.com

Share capital € 11,019,314.98 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

Not for distribution, directly or indirectly, in the United States of America, Australia, Canada or Japan

TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company's shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)

For further information:

Marina Del Bue

General Manager Corporate Governance & Administration

Investor Relations Director *ad int.*

MolMed S.p.A.

phone: +39 02 21277.371

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com

Press agent

Federico Ferrari

SEC Relazioni Pubbliche e Istituzionali srl

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: ferrari@secp.it

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.